The Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) is a longitudinal study launched in 2006 to identify biomarkers, cognitive characteristics, and lifestyle factors associated with the development of [Alzheimer's Disease](/diseases/alzheimers-disease).[@aibl2023] AIBL is one of the world's largest and most comprehensively characterized cohorts for Alzheimer's research, with over 1,500 participants followed for more than 15 years.
Study Design
...
Australian Imaging Biomarker Lifestyle Flagship Study of Ageing (AIBL)
Introduction
Mermaid diagram (expand to render)
The Australian Imaging, Biomarker and Lifestyle Flagship Study of Ageing (AIBL) is a longitudinal study launched in 2006 to identify biomarkers, cognitive characteristics, and lifestyle factors associated with the development of [Alzheimer's Disease](/diseases/alzheimers-disease).[@aibl2023] AIBL is one of the world's largest and most comprehensively characterized cohorts for Alzheimer's research, with over 1,500 participants followed for more than 15 years.
Study Design
AIBL employs a multi-phase longitudinal cohort design with three main diagnostic groups:[@pemberton2015]
Cognitively Normal (CN): Healthy older adults with no cognitive impairment
Mild Cognitive Impairment (MCI): Individuals with subtle cognitive deficits[@rami2014]
Alzheimer's Disease (AD): Individuals meeting clinical criteria for AD
The study includes both a discovery cohort and an active enrollment arm to continuously refresh the participant pool.
Key Objectives
Early Detection: Identify biomarkers for early detection of AD before clinical symptoms[@jessen2014]
Risk Factor Analysis: Understand lifestyle and genetic risk factors[@fagan2023]
Disease Progression: Track biomarker changes over time[@lopresti2015]
Therapeutic Development: Enable better clinical trial design and participant selection
MRI: Structural brain imaging to measure hippocampal atrophy and cortical thickness
PET: Amyloid imaging using Pittsburgh compound B (PiB) and florbetapir
FDG-PET: Glucose metabolism assessments
DWI: Diffusion weighted imaging for white matter integrity
Biospecimens
Cerebrospinal Fluid (CSF): Biomarker analysis including Aβ42, total tau, and phosphorylated tau
Blood: Plasma and serum for biomarker studies, including Aβ40, Aβ42, and inflammatory markers
DNA/RNA: Genetic and genomic analyses for APOE and other risk genes
Clinical Assessments
Cognitive Testing: Comprehensive neuropsychological batteries including MMSE, CAMCOG, and domain-specific tests
Psychiatric Assessment: Mood and behavioral evaluations[@mortby2012]
Lifestyle Questionnaire: Detailed assessment of physical activity, diet, and social engagement
Functional Assessment: Activities of daily living and functional capacity[@elias2000]
Major Findings
Amyloid Prevalence
AIBL has demonstrated that approximately 20-30% of cognitively normal older adults over age 65 have elevated amyloid in the brain, consistent with preclinical AD[@fagan2023]
Biomarker Trajectories
The study has established that amyloid accumulation begins 10-15 years before clinical symptoms, following a predictable sequence of biomarker changes[@villemagne2017]
Lifestyle Factors
AIBL has contributed important insights into modifiable risk factors including physical activity, diet, and cognitive engagement[@aibl2023]
Cognitive Reserve
Higher educational attainment and cognitively stimulating activities are associated with greater cognitive resilience despite amyloid pathology[@rami2014]
Impact on Alzheimer's Research
AIBL has significantly advanced the field by:[@pemberton2015]
Providing validation data for amyloid PET tracers
Establishing baseline rates of amyloid positivity in the Australian population
Enabling longitudinal studies of biomarker progression
Contributing to international harmonization efforts
Participating Institutions
AIBL involves major research institutions across Australia, including:
CSIRO (Commonwealth Scientific and Industrial Research Organisation)
University of Melbourne
Austin Health
Edith Cowan University
Macquarie University
The study is funded by the National Health and Medical Research Council (NHMRC) of Australia and commercial partners.
Data Access
AIBL data are available to qualified researchers through:[@pemberton2015]
The AIBL data portal (registration required)
The Australian Imaging, Biomarker and Lifestyle platform
Collaborative analysis agreements with the AIBL team
Future Directions
AIBL continues to expand with:[@aibl2023]
Integration with other international cohort studies
Advanced biomarker development including blood-based biomarkers
Focus on early intervention and prevention trials
Expansion of the prodromal and preclinical cohorts